{"id":"W2139891818","doi":"10.1200/jco.2011.38.0402","title":"Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":990,"is_retracted":false,"has_abstract":true,"ca_institutions":"Seagen (Canada)","funders":"Takeda Oncology","keywords":"Brentuximab vedotin; Medicine; Anaplastic large-cell lymphoma; Internal medicine; Neutropenia; Antibody-drug conjugate; Phases of clinical research; Refractory (planetary science); Oncology; CD30; Adverse effect; Lymphoma; Gastroenterology; Chemotherapy; Immunology; Antibody; Monoclonal antibody","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00319185,0.0002270051,0.002129924,0.0002478317,0.00004543801,0.000004300372,0.0001545336,0.0003048943,0.00004138225],"category_scores_gemma":[0.002811887,0.0001268417,0.0002705371,0.0002617084,0.00009434174,0.0001691343,0.00007828018,0.0003895775,0.00001393253],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000583372,"about_ca_system_score_gemma":0.001583723,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003538698,"about_ca_topic_score_gemma":0.00008038376,"domain_scores_codex":[0.9943848,0.0007306376,0.003597907,0.0002449625,0.0006275878,0.0004141675],"domain_scores_gemma":[0.9929075,0.002702887,0.003145382,0.0003277029,0.0004262275,0.0004902562],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.08750263,0.269597,0.6161203,0.00005500649,0.0004323373,0.0006992387,0.0006238963,0.000002412259,0.000007249552,0.000002669077,0.001331133,0.02362612],"study_design_scores_gemma":[0.2913716,0.1708482,0.5330142,0.000354415,0.0007104037,0.00008739443,0.0004292887,0.0000112691,0.00001855691,9.616061e-7,0.00306997,0.00008373948],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9971379,0.0005109746,0.000004516281,0.0001884553,0.00100257,0.0006911681,0.00002715024,0.000007393602,0.0004298814],"genre_scores_gemma":[0.9987565,0.0001331538,0.0003499395,0.0002062886,0.0003666779,0.00001301524,0.00000985361,0.00002372428,0.000140879],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2038689,"threshold_uncertainty_score":0.5172456,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05924066866749524,"score_gpt":0.4100624161401102,"score_spread":0.350821747472615,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}